ICO

Search documents
Combined General Meeting of July 22, 2025 Conditions for Obtaining the Preparatory Documents
Globenewswire· 2025-07-01 16:00
COMBINED GENERAL MEETINGOF JULY 22, 2025 CONDITIONS FOR OBTAINING THE PREPARATORY DOCUMENTS Bernin (Grenoble), France, on July 1, 2025 - Soitec (Euronext Paris) reminds that the Company’s shareholders are invited to attend the Annual General Meeting to be held on Tuesday July 22, 2025 at 9:30 a.m. (Paris time), in the Auditorium of the VERSO conference Center located at 52 rue de la Victoire, 75009 Paris, France. The preliminary meeting notice serving as convening notice as provided for in Article R. 225-73 ...
自研 M 芯片五周年,苹果站在时代的交界点,和 Intel 挥手道别
3 6 Ke· 2025-07-01 10:18
ARM Mac 五周年 当我们谈论 macOS Tahoe 时,我们在谈论什么? 大部分讨论都集中在这个全新的液态玻璃设计,或者消失的启动台,还有那个变来变去的访达图标。 但或许没那么为人所知的是,macOS Tahoe 将会是最后一代支持 Intel 处理器 Mac 的版本,不过苹果承诺,还会为升级 Tahoe 的老 Mac 提供三年 的安全更新。 苹果也同时宣布,后年的 macOS 28 将不再包含完整的 Rosetta 2,只包含部分组件,运行那些不会再更新的老应用和游戏。 也就是说,macOS Tahoe 既可以说是苹果全新时代的开始,也是一个旧时代的落幕。 押注 Intel 不如押注自己 现在看来,Mac 从ARM 到 Intel 的过渡走得相当平稳,甚至比当年从 PowerPC 上转移到 Intel 还要更丝滑,并且为苹果带来了丰厚的回报,但在当 时,外界并没有那么看好 Mac 自研芯片。 主要原因是两个:从 x86 转变为 ARM,意味着苹果将抛弃 15 年来的应用生态积累;也有不少偏见,认为「ARM」芯片是手机专属,无法处理 「桌面级」的繁重任务,x86 芯片依旧是干重活的首选。 并且隔壁家的 ...
中国晶圆制造设备行业的现状与未
2025-07-01 00:40
更多资料加入知识星球:水木调研纪要 关注公众号:水木Alpha China's Wafer Fab Equipment Industry Present & Future Covering the present tools & future roadmap of NAURA, AMEC, ACM Research, SiCarrier and Piotech ZEPHYR JUN 29, 2025 5 Share Source: CGTN The advent of LLMs and the intensication of the US-China rivalry have placed semiconductors at the undisputed center of global power dynamics. While headlines frequently focus on the progress of Chinese chip designers like Huawei and foundries such as SMIC and CXMT, a critical yet far mor ...
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities
Globenewswire· 2025-06-30 23:52
Core Viewpoint - Achieve Life Sciences, Inc. has successfully closed a public offering of 15 million shares of common stock, raising gross proceeds of $45 million to advance the development of cytisinicline for nicotine dependence treatment [1][2]. Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence, with a New Drug Application submitted to the FDA in June 2025 [5]. - The company has completed two Phase 3 studies and an open-label safety study for cytisinicline, and has also conducted a Phase 2 study for vaping cessation [5]. Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, aimed at reducing nicotine cravings and the satisfaction derived from nicotine products [7]. - Approximately 29 million adults in the U.S. smoke combustible cigarettes, and tobacco use is the leading cause of preventable death globally, with over 8 million deaths annually [6]. - There are currently no FDA-approved treatments specifically for nicotine e-cigarette cessation, highlighting a critical need that cytisinicline aims to address [6]. Financial Details - The public offering included 15 million shares at a price of $3.00 per share, along with warrants to purchase up to 16,766,666 additional shares [1]. - Proceeds from the offering will be used for advancing cytisinicline towards FDA marketing approval and for general corporate purposes [2].
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
Prnewswire· 2025-06-30 20:05
SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants. NBIP-01435 is a long-acting corticotropin-releasing factor type 1 receptor antagonist administered as a subcutaneous injection for the potential treatment of congenital adrenal hyperplasia (C ...
X @TechCrunch
TechCrunch· 2025-06-30 18:35
Privacy-focused app maker Proton sues Apple over alleged anticompetitive practices and fees | TechCrunch https://t.co/N2zh4giK8D ...
Chip “Make in Vietnam”: VIẾT TIẾP GIẤC MƠ CỦA CHA ANH | Vinh Quang Nguyễn | TEDxFTU Hanoi
TEDx Talks· 2025-06-30 16:46
Để bắt đầu về cái bài nói ngày hôm nay thì tôi muốn kể với các bạn về cái câu chuyện một cái hành trình của hạt gạo. Việt Nam chúng ta có một cái câu chuyện rất hay, rất đáng tự hào đấy là hành trình hạt gạo. À nếu Việt Nam là nước nông nghiệp của ngô nước và các cái hệ trước của chúng ta, thế hệ tra anh, thế hệ trước nữa đã cố gắng để phát triển Việt Nam đưa cái nền nông nghiệp ngôn nước của chúng ta để phát triển.À ở thời điểm hiện tại năm 2024 thì chúng ta sẽ đạt được khoảng năm sân khẩu khoảng 5 triệu 8 ...
Jury deliberations underway in Sean 'Diddy' Combs trial
NBC News· 2025-06-30 16:39
Meanwhile, jury deliberations are currently underway in Shawn Diddy Combmes's federal sex trafficking trial. The court heard from 34 witnesses over the course of seven weeks. Among them, Combmes's former girlfriend, Cassie Ventura, who detailed years of alleged abuse.Prosecutors say that Combmes ran a criminal enterprise and allegedly sex trafficked Ventura as well as another former girlfriend. We'll call her Jane. The defense says the disgraced rat mogul is being unfairly persecuted for his sexual lifestyl ...
估值超1600亿,长江存储母公司获员工持股平台入股
Guan Cha Zhe Wang· 2025-06-30 15:09
Core Viewpoint - Changjiang Storage's parent company, Changjiang Storage Technology Holding Co., Ltd. (Chang控集团), has undergone a change in its business registration, increasing its registered capital from 111.81207 billion to 113.27896 billion yuan, marking an increase of approximately 1.467 billion yuan [1]. Group 1: Shareholder Changes - New shareholders include Wuhan Smart Chip Plan No. 1 Enterprise Management Partnership (Limited Partnership) holding 0.2295% and Wuhan Smart Chip Plans No. 2 to No. 6, each holding 0.2131%, totaling 1.295% with a subscribed capital of 1.4668966 million yuan [2]. - The new shareholders are structured in a dual-layer nested format, with the second to fifth partnerships having a total of 24 underlying partnerships, all named under the "Smart Chip Plan" [2]. Group 2: Employee Stock Ownership Plan - The newly added Smart Chip Plan serves as an employee stock ownership platform primarily for senior management and technical staff of Chang控集团 [5]. - An increase of 2.127 billion yuan (1.295% of total registered capital) is planned for the employee stock ownership platform, which is currently in preparation [5]. Group 3: Company Valuation and Business Overview - Chang控集团's valuation is estimated to reach 164.25 billion yuan, with its core business encompassing the R&D and production of 3D NAND flash memory, embedded storage chips, and solid-state drives [5]. - Changjiang Storage has been recognized as a significant flash memory manufacturer in China, recently entering the Hurun Research Institute's 2025 Global Unicorn List with a valuation of 160 billion yuan [5]. Group 4: Recent Investments - On April 25, 2023, Huangyuan Zhihui Beverage Co., Ltd. announced a 1.6 billion yuan investment in Chang控集团, resulting in a 0.99% stake [6]. - Following the entry of the employee stock ownership platform, the number of shareholders in Chang控集团 has expanded to 29, diluting the holdings of existing shareholders [6].